UCLA Health
myUCLAhealth
School of Medicine
Toggle navigation
About Us
What is UCLA Health?
Contact Us
Your Feedback
Accountable Care Organization
Awards & Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
In the Community
340B Program
Industry Relations
Innovation
Leadership
News Releases
Price Transparency
Social Media
Contact
Your Feedback
Accountable Care Organization
Awards and Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
340B Program
Leadership
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
Conditions & Treatment
Health Library
Tests & Procedures
Drug Interaction Checker
Brain & Nervous System
Cancer
Children's Health
Heart Disease
Nutrition & Wellness
Pregnancy & Newborns
Orthopedics
Women's Health
Video Library
Cancer
Cardiovascular
Chiropractic
Cosmetic Surgery
Ear, Nose and Throat
Gastrointestinal
General Healthcare
Neurological
Obstetrics/Gynecology
See all videos...
Video Library
Locations
Hospitals
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
UCLA Mattel Children's Hospital
Resnick Neuropsychiatric Hospital
Institutes and Centers
Take a Virtual Tour
Medical Offices/Clinics
Primary Care
Specialty Care
Urgent Care Centers
Outpatient Surgery Centers
Community Cancer Care
Imaging/Radiology Locations
Clinical Labs
Pharmacies
Interactive Map
Locations Coming Soon
UCLA Hospitals
Take a Virtual Tour
Primary Care Practices
Specialty Care Practices
Urgent Care Centers
Outpatient Surgery Centers
Other Locations
Interactive Map
Coming Soon!
Medical Services
For Patients & Visitors
Directions & Parking
Appointments: Call, Click, Come In
Admissions Information
Preparing For Surgery
Patient Services
Security & Parking Services
Office of the Patient Experience
For International Patients
Lodging & Nearby Services
Around Westwood
Gift Shops & Flowers
Health Resources
Log in to myUCLAhealth
Billing and Insurance Information
Medical Records
Accountable Care Organization (ACO)
Price Transparency
Interactive Patient Education Videos (Emmi)
FAQs
Calendar of Events
Secure Email Messages
Share Your Story
Health Publications
Vital Signs Newsletters
Health Tips for Parents
Contact Us
Appointments: Call, Click, Come in
Admissions Information
Advance Directive
Directions & Parking
Patient Services
Medical Records
myUCLAhealth
Smoke-Free
Publications
Health Resources
Around Westwood
Lodging
Preparing For Surgery
Patient-focused Technology Council
Health Forms
End of Life Option Act: Resources & Materials
Frequently Asked Questions
Secure Email Messages
Gift Shops
For Healthcare Professionals
Referring a Patient
Continuing Medical Education
Ethics Center
UCLA HealthLink
Physician to Physician Access Line (P2P)
David Geffen School of Medicine at UCLA
Clinical Informatics Fellowship
Academic Positions
Physician Careers
UCLA School of Dentistry
UCLA School of Nursing
Department of Nursing
Physician Publications
Physicians Update
Clinical Updates
U Magazine
Physician to Physician Access Line (P2P)
Physician Careers
Clinical Informatics Fellowship
Flu Resources for Healthcare Professionals
Publications
Multimedia
UCLAMDCHAT Webinars
Community Health Program Videos
iTunes
Download Our Apps
Mini Med School
Demystifying Cancer Forum
TEDx UCLA Videos
Tips from our Physical Therapists
Patient Stories
Real Questions
Webinars on Demand
Pediatric Grand Rounds
Community Health Program Videos
UCLAMDChat Webinars
iTunes
Download Our Apps
Mini Med School
Demystifying Cancer Forum
TEDx UCLA Videos
Tips From Our Physical Therapists
Patient Stories
Real Questions
Back Pain Management
Find a Provider
UCLA Health
myUCLAhealth
School of Medicine
About Us
About Us
About Us
Contact
Your Feedback
Accountable Care Organization
ACO - Anthem Blue Cross PPO
Anthem Blue Cross PPO ACO FAQ
Awards and Achievements
UCLA Health hospitals again rank No. 1 in Los Angeles, No. 7 nationally
UCLA Designated a National Magnet Hospital
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
Community Health
340B Program
Leadership
Dr. John Mazziotta
Johnese Spisso
Dr. Kelsey Martin
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
About Us
Contact
Your Feedback
Accountable Care Organization
Awards and Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
340B Program
Leadership
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
Home
About Us
News Releases
News Releases
Share this
Health and Behavior
UCLA researchers develop biomarker for rapid relief of major depression
09/10/2009
It is a long, slow slog to treat major depression. Many antidepressant medications are available, but no single biomarker or diagnostic test exists to predict which one is right for an individual. As a result, for more than half of all patients, the first drug prescribed doesn't work, and it can take months to figure out what does.
Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.
The study, called the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression, or BRITE-MD, measured changes in brain-wave patterns using quantitative electroencephalography (QEEG), a non-invasive, computerized measurement that recognizes specific alterations in brain-wave activity. These changes precede improvement in mood by many weeks and appear to serve as a biomarker that accurately predicts how effective a given medication will be. The study results appear in two articles published in the September issue of the journal Psychiatry Research.
Nine sites around the country collaborated on the study, which enrolled a total of 375 people who had been diagnosed with major depressive disorder (MDD). Each individual was given a baseline QEEG at the beginning of the trial and then prescribed the antidepressant escitalopram, commonly known as Lexapro, one of a class of drugs known as selective serotonin re-uptake inhibitors that are commonly prescribed for depression. After one week, a second QEEG was taken. The researchers examined a biomarker called the antidepressant treatment response (ATR) index — a specific change in brain-wave patterns from the baseline QEEG.
Subjects were then randomly assigned to continue with escitalopram or were given a different drug. A total of 73 patients who remained on escitalopram were tracked for 49 days to see if their results matched the prediction of the ATR biomarker. The ATR predicted both response and remission with an accuracy rate of 74 percent, much higher than any other method available. The researchers also found that they could predict whether subjects were more likely to respond to a different antidepressant, bupropion, also known as Wellbutrin XL.
"Until now, other than waiting, there has been no reliable method for predicting whether a medication would lead to a good response or remission," said Dr. Andrew Leuchter, professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA and lead author of the study. "And that wait can be as long as 14 weeks. So these are very exciting findings for the patient suffering from depression. The BRITE results are a milestone in our efforts to develop clinically useful biomarkers for predicting treatment response in MDD."
Major depressive disorder is a leading cause of disability, costing society in excess of $80 billion annually; approximately two-thirds of these costs reflect the enormous disability associated with the disorder. An estimated 15 million people in the United States experience a depressive episode each year, and nearly 17 percent of adults will experience major depression in their lifetime.
"BRITE study results suggest that the ATR biomarker could potentially provide the greatest clinical benefit for those patients who might be receiving a medication that is unlikely to help them," Leuchter said. "Our results suggest that it may be possible to switch these patients to a more effective treatment quickly. This would help patients and their physicians avoid the frustration, risk and expense of long and ineffective medication trials."
Leuchter noted that research has shown that depression patients who do not get better with a first treatment experience prolonged suffering, are more likely to abandon treatment altogether and may become more resistant to treatment over time.
"So the benefits to the individual and to society are enormous," he said.
An added benefit of the biomarker test, according to Leuchter, is that it is non-invasive, painless and fast — about 15 minutes — and only involves the placement of six electrodes around the forehead and on the earlobes.
Aspect Medical Systems, which developed the ATR biomarker, provided financial support for the study. Aspect also participated in the design and conduct of the study; the collection, management, analysis and interpretation of the data; and the preparation and review of the manuscript. Final approval of the form and content of the manuscript rested with the authors.
Other UCLA authors included Dr. Ian Cook, Dr. Karl S. Burgoyne and Dr. James T. McCracken. Leuchter is chair of Aspect's neuroscience advisory board and has provided scientific consultation to them.
The Semel Institute for Neuroscience and Human Behavior
is an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior and the causes and consequences of neuropsychiatric disorders. In addition to conducting fundamental research, institute faculty seek to develop effective treatments for neurological and psychiatric disorders, improve access to mental health services and shape national health policy regarding neuropsychiatric disorders.
For more news, visit the
UCLA Newsroom
or follow us on
Twitter
.
Media Contact:
Mark Wheeler
(310) 794-2265
mwheeler@mednet.ucla.edu
Media Contact
Mark Wheeler
(310) 794-2265
mwheeler@mednet.ucla.edu
Latest News
Health and Behavior
Low-income undocumented adults are largely locked out of health care in California, study finds
02/19/2019
Nine in 10 lack insurance.
Health and Behavior
UCLA faculty voice: Adolescents have a fundamental need to contribute
02/19/2019
No longer children but not yet adults, adolescents need opportunities to learn and prepare for their entrance into the broader society.
Health and Behavior
Sexually transmitted infections are on the rise. Here’s what you need to know to protect yourself
02/14/2019
In a Q&A, UCLA’s Dr. Leena Nathan explains which infections sexually active people are more likely to be exposed to and to contract.
Health and Behavior
Electrical activity early in fruit flies’ brain development could shed light on how neurons wire the brain
02/12/2019
A study by UCLA neuroscientists suggests that the signals could help neurons find each other to form networks.
Health and Behavior
For recurrent glioblastoma, immunotherapy before surgery appears to help more than afterward
02/11/2019
“We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it,” said UCLA's Dr. Timothy Cloughesy.
Like Us on Facebook
Follow Us on Twitter
Subscribe to Our Videos on YouTube
Follow us on Instagram
Connect with Us on LinkedIn
Follow us on Pinterest
Follow us on Flickr
Follow us on Sharecare
×
Sign in to myUCLAhealth